Seeking Alpha

Mela Sciences (MELA +11.6%) rises after an article in Barron's over the weekend cites a Needham...

Mela Sciences (MELA +11.6%) rises after an article in Barron's over the weekend cites a Needham analyst who says the recent FDA approval of MelaFind could push the stock as high as $20 over the next year.
Comments (1)
  • jrusso9722
    , contributor
    Comments (94) | Send Message
     
    An entire generation of people will embark on the remainder of their life, with a better chance at life. On the day that MelaFind identifies a non-typical lesion as "cannot rule out Melanoma", the patient will benefit. Early detection saves lives. MelaFind will save lives. MelaFind will help a dermatologist save lives. Because of that, we believe MelaFind will be a success. Because of that success, investors will benefit.
    9 Nov 2011, 06:23 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|